Annual Cash & Cash Equivalents
$121.47 M
+$44.13 M+57.06%
December 31, 2023
Summary
- As of February 7, 2025, LXEO annual cash & cash equivalents is $121.47 million, with the most recent change of +$44.13 million (+57.06%) on December 31, 2023.
- During the last 3 years, LXEO annual cash & cash equivalents has risen by +$92.09 million (+313.53%).
- LXEO annual cash & cash equivalents is now -10.59% below its all-time high of $135.86 million, reached on December 31, 2021.
Performance
LXEO Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$157.02 M
-$17.96 M-10.26%
September 30, 2024
Summary
- As of February 7, 2025, LXEO quarterly cash and cash equivalents is $157.02 million, with the most recent change of -$17.96 million (-10.26%) on September 30, 2024.
- Over the past year, LXEO quarterly cash and cash equivalents has increased by +$121.57 million (+342.95%).
- LXEO quarterly cash and cash equivalents is now -19.50% below its all-time high of $195.06 million, reached on March 31, 2024.
Performance
LXEO Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
LXEO Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +57.1% | +342.9% |
| 3 y3 years | +313.5% | +342.9% |
| 5 y5 years | +313.5% | +342.9% |
LXEO Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -10.6% | +57.1% | -19.5% | +342.9% |
| 5 y | 5-year | -10.6% | +313.5% | -19.5% | +342.9% |
| alltime | all time | -10.6% | +313.5% | -19.5% | +342.9% |
Lexeo Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $157.02 M(-10.3%) |
| Jun 2024 | - | $174.98 M(-10.3%) |
| Mar 2024 | - | $195.06 M(+60.6%) |
| Dec 2023 | $121.47 M | $121.47 M(+242.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2023 | - | $35.45 M(-22.2%) |
| Jun 2023 | - | $45.54 M(-41.1%) |
| Dec 2022 | $77.33 M(-43.1%) | $77.33 M |
| Dec 2021 | $135.86 M(+362.5%) | - |
| Dec 2020 | $29.37 M | - |
FAQ
- What is Lexeo Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Lexeo Therapeutics?
- What is Lexeo Therapeutics annual cash & cash equivalents year-on-year change?
- What is Lexeo Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Lexeo Therapeutics?
- What is Lexeo Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Lexeo Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of LXEO is $121.47 M
What is the all time high annual cash & cash equivalents for Lexeo Therapeutics?
Lexeo Therapeutics all-time high annual cash & cash equivalents is $135.86 M
What is Lexeo Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, LXEO annual cash & cash equivalents has changed by +$44.13 M (+57.06%)
What is Lexeo Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of LXEO is $157.02 M
What is the all time high quarterly cash and cash equivalents for Lexeo Therapeutics?
Lexeo Therapeutics all-time high quarterly cash and cash equivalents is $195.06 M
What is Lexeo Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, LXEO quarterly cash and cash equivalents has changed by +$121.57 M (+342.95%)